Background It was urgent and necessary to synthesize the evidence for vaccine
effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a …

It has been more than three years since the first emergence of coronavirus disease 2019
(COVID-19) and millions of lives have been taken to date. Like most pandemics caused by …

Background The ZF2001 vaccine, which contains a dimeric form of the receptor-binding
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …

Summary Background By March, 2023, 54 countries, areas, and territories (hereafter CAT) in
the WHO European Region had reported more than 2· 2 million COVID-19-related deaths to …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disclose the variants of
concern (VOC) including Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P1), Delta (B. 1.617. 2) …

Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD
conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity …

Background In Hungary, the pandemic waves in late 2021 and early 2022 were dominated
by the Delta and Omicron SARS-CoV-2 variants, respectively. Booster vaccines were offered …

People living with HIV (PLHIV) are at higher risk of poor outcomes of SARS-CoV-2 infection.
Here we report the pooled prevalence of COVID-19 vaccine acceptance/uptake and …

COVID‐19 vaccine is critical in preventing SARS‐CoV‐2 infection and transmission.
However, obesity's effect on immune responses to COVID‐19 vaccines is still unknown. We …

Background The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have
been widely used to control the COVID-19 pandemic. The influence of multiple factors on …